Analyst firms · Citigroup · IART
Citigroup IART price target and rating history
Integra LifeSciences Holdings Corporation (IART) · Health Care
Citigroup rates Integra LifeSciences Holdings Corporation (IART) Neutral with a $16 price target, as of its latest action on May 28, 2026. It has published 4 rating actions on IART since May 2023, including 2 upgrades and 2 downgrades. Across 4 firms with a IART price target in the last 12 months, the median target is $19. Citigroup's $16 is 16% below that.
- Current rating
- Neutral
- Price target
- $16
- Median target, all firms
- $19
- Actions on IART
- 4
Citigroup price target on IART
Every Citigroup rating on IART
- May 28, 2026
- Jul 30, 2024
- Apr 3, 2024
- May 23, 2023
How other firms rate IART
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $19 | Jul 28, 2026 |
| BMO Capital Markets | Market Perform | $19 | Jul 9, 2026 |
| Argus Research | Buy | $25 | Jun 18, 2026 |
| Citigroup | Neutral | $16 | May 28, 2026 |
Questions about Citigroup and IART
- What is Citigroup's price target for IART?
- Citigroup's latest stated price target for Integra LifeSciences Holdings Corporation (IART) is $16, from its action on May 28, 2026.
- What is Citigroup's rating on IART?
- Citigroup rates IART Neutral, a neutral rating, as of May 28, 2026.
- When did Citigroup last change its view on IART?
- On May 28, 2026, Citigroup upgrades to Neutral from Sell, price target $16.
- How does Citigroup's IART target compare with other analysts?
- Across 4 firms with a IART price target in the last 12 months, the median target is $19. Citigroup's $16 is 16% below that.
More IART rating histories
All Citigroup ratingsIART news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.